Trial Profile
Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mercaptopurine and Methotrexate for Patients With Untreated Acute Promyelocytic Leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Cytarabine; Daunorubicin; Mercaptopurine; Methotrexate; Tretinoin
- Indications Acute promyelocytic leukaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- 12 Sep 2005 New trial record.